Join List

The surge of the coronavirus pandemic has made our society increasingly aware of the threats posed by viral diseases. One of the most terrifying viral infections is HIV leading to AIDS. While the HIV epidemic can be considered under control thanks to small molecules (combined anti-retroviral therapy or cART), a definitive cure for the disease remains elusive.

In this minireview Dr. Dennis Koester explains why emerging small molecule LAIs may bring about a paradigm shift in HIV treatment, discussing:

  • The current standard of care for HIV treatment
  • The problem of drug resistance
  • Why emerging small molecule LAIs such as cabotegravir and lenacapavir are promising
Continue Reading
exclusive career opportunity
The inventor of Lyrica, one of Pfizer's biggest selling drugs, is looking for a CEO to lead an early-stage biotech company. AKAVA has been financed with several million dollars and houses multiple novel drugs for cancer and neuro indications. It is preclinical with the aim to file the IND by year-end and begin FIH dosing in 2H 2023.

The company is looking for an experienced biotech executive with an entrepreneurial spirit, strong communication/presentation skills, previous success bringing a drug through the clinic, and the ability and experience to raise significant capital ($20M+) to fund clinical operations. Experience transitioning to the public markets is also a plus. Compensation will have both a cash and equity component. If interested, please contact Drug Hunter directly by replying to this e-mail with a description of your background and copy of your CV/resume.
See All Careers
Share an Opportunity
more recent content
Here's a recap of other stories recently published on Drug Hunter:
  1. Emerging Technologies and Modalities Review
  2. Intro to Fragment-Based Drug Discovery
  3. Ton-Scale Synthesis of a Paxlovid Intermediate
  4. Drug Discovery IPOs in 2022Q1
  5. AICS and PAINS: Mechanisms of Assay Interference
  6. 2021 Novel Drugs for Genetic Diseases Deep Dive
  7. What is an IND? Why Do Clinical Holds Happen?
  8. FDA Novel Drug Approvals: April 2022
  9. Why Did GSK Pay $1.9B for Momoletinib?
  10. Molecules of the Month - Mar. 2022
  11. Practical PK Calculators
  12. Drug Discovery M&A Upfront Payments in 2021
Want to dive deeper into the science behind industrial drug discovery? Get access to Premium for your team at a group rate (e.g. 5+ for $29/mo each) by contacting us.
share Drug Hunter
Know drug hunters that would find this newsletter helpful? Give them your unique referral link (below) to let them sign up too. We'll be raffling off fun things to top referrers, stay tuned~
PS: You have referred <<RH_TOTREF>> people so far
discover together

Join List
Copyright © 2022 Drug Hunter Inc., All rights reserved.
You can change how often you receive messages by updating your preferences or remove yourself from this list. Having trouble? Contact us directly.